Camberlogo (Camberlogo)
Pregabalin Capsule
Product Images NDC 71335-3158
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-3158). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Label (Lbl713353158)
Pregabalin Capsules 300 mg oral dosage form packaging label with quantity indicated as 60 capsules. The label includes the NDC number 71335-3158-1 and states the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Hetero Labs Limited. Storage instructions specify 25°C with allowable excursions. A barcode and QR codes are visible on the label.*
Pregabalinfigure1 (Pregabalinfigure1)
A line graph showing percent improvement in pain from baseline on the X-axis and percent of patients improved on the Y-axis, comparing Pregabalin at 25 mg, 100 mg, and 200 mg three times a day doses versus placebo. The graph illustrates differences in patient improvement over time among these groups.*
Pregabalinfigure10 (Pregabalinfigure10)
A Kaplan-Meier survival curve graph comparing the estimated percentage of subjects without LTR (likely 'loss to remission' or similar endpoint) over a period of 180 days. Two lines represent treatment groups: Pregabalin (solid line) and Placebo (dashed line), plotted with percentage on the Y-axis and days on the X-axis.*
Pregabalinfigure11 (Pregabalinfigure11)
A line graph depicting the percent of subjects improved over time from baseline to Week 12 BOCF. The x-axis shows percent improvement ranging from >0 to 100, and the y-axis shows the percent of subjects improved ranging from 0% to 100%. Two lines represent Pregabalin and Placebo, illustrating greater improvement with Pregabalin compared to Placebo.*
Pregabalinfigure12 (Pregabalinfigure12)
A line graph depicting the percent of subjects improved from baseline to week 16 BOCF, comparing Pregabalin (solid line) and Placebo (dashed line). The x-axis represents percent improvement from 0 to 100%, and the y-axis represents the percent of subjects improved from 0 to 100%. The graph shows greater improvement in subjects treated with Pregabalin versus Placebo over the range.*
Pregabalinfigure2 (Pregabalinfigure2)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day and placebo. The graph illustrates that a higher percentage of patients improved with Pregabalin across varying levels of pain improvement.*
Pregabalinfigure3 (Pregabalinfigure3)
A line graph depicting the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice a day, Pregabalin 150 mg twice a day, Pregabalin 75 mg twice a day, and a placebo. The Pregabalin 300 mg group consistently shows the highest percent of patients improved across levels of pain improvement, followed by the 150 mg and 75 mg groups, with placebo showing the lowest improvement.*
Pregabalinfigure4 (Pregabalinfigure4)
Line graph depicting the percent of patients improved relative to percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The graph compares patient improvement rates across these three treatment groups over a range of pain improvement percentages.*
Pregabalinfigure5 (Pregabalinfigure5)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline, comparing three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of pain improvement across the different treatments.*
Pregabalinfigure6 (Pregabalinfigure6)
A bar chart presenting responder rates (%) from two clinical studies, E1 and E3, for Pregabalin at various dosages compared to placebo. Study E1 shows responder rates for placebo and 50, 150, 300, and 600 mg/day dosages given twice daily (BID). Study E3 shows placebo and 600 mg/day dosages given twice daily (BID) and three times daily (TID). Statistically significant results versus placebo are indicated.*
Pregabalinfigure7 (Pregabalinfigure7)
A line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day. The graph includes data points from four studies (E1 BID, E2 TID, E3 BID, E3 TID) with statistical significance p-values indicated for each dose level. The x-axis represents dose (mg/day) up to 600, and the y-axis represents seizure reduction percentage up to 60%. Placebo dose is noted as zero dose.*
Pregabalinfigure8 (Pregabalinfigure8)
A bar graph depicting responder rates in percentage for Pregabalin at different dosages compared to placebo. The x-axis shows three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day, with corresponding responder rates of 22.6%, 29.1%, and 40.6%. Sample sizes are noted below each group.*
Pregabalinfigure9 (Pregabalinfigure9)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 600 mg, 450 mg, and 300 mg daily compared to placebo. The x-axis represents percent pain improvement from baseline, and the y-axis shows the percent of patients improved.*
Pregabalinstructure (Pregabalinstructure)
Chemical structure of Pregabalin showing its molecular components including amine (NH2), carboxyl (COOH), and hydrocarbon groups.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
